Business Context and Reporting Period
Prestige Consumer Healthcare Inc. (PBH) filed this Form 8-K on May 13, 2026. The report covers two primary events: the announcement of financial results for the fiscal quarter and year ended March 31, 2026, and the entry into a material definitive agreement for an acquisition in Australia.
Key Financial Metrics and Transaction Details
Acquisition Transaction:
- Target: A portfolio of Australian companies (LaCorium Health, Stantail Trading, Stantail International, Brands Worldwide Holdings, and Laderma Holdings) specializing in therapeutic skin care.
- Consideration: Approximately $150 million in cash, subject to adjustments for indebtedness and other terms.
- Expected Closing: Second quarter of fiscal 2027.
Financial Results:
- The filing references a press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) containing specific revenue, profit, cash flow, and margin data for the period ended March 31, 2026.
- Note: The specific numerical values for revenue, profit, cash flow, margins, debt, and liquidity are not contained within the text of this 8-K summary; they are located in the referenced exhibits.
Material Changes and Outlook
Material Change: The Company has entered a definitive agreement to expand its footprint in the Australian therapeutic skin care market. This represents a significant capital deployment of approximately $150 million.
Outlook and Management Commentary:
- Management expects the transaction to close in Q2 fiscal 2027, subject to customary conditions.
- The Company utilized an investor presentation to discuss the March 31, 2026 results and intends to use this presentation for future investor and analyst meetings during fiscal 2027.
Risks, Contingencies, and Unusual Items
- Closing Conditions: The transaction is subject to satisfaction or waiver of customary closing conditions.
- Termination Rights: Either party may terminate the agreement prior to October 1, 2026, if the other party breaches the agreement and fails to cure such breach.
- Indemnification: The Purchaser has obtained warranty and indemnity insurance as its sole recourse for losses related to breaches of representations and warranties, except in cases of fraud.
- Regulatory Disclosure: Information in the investor presentation is not deemed "filed" under the Exchange Act unless specifically incorporated by reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2026 revenue, earnings, and cash flow figures.
- Verify the final purchase price and closing date of the Australian acquisition in future filings (expected in the 10-Q for the quarter ended June 30, 2026).
- Assess the impact of the $150 million cash outlay on the Company's liquidity and debt covenants.
- Monitor the satisfaction of closing conditions for the transaction, with a termination deadline of October 1, 2026.